Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges

Purpose of review This update discusses novel aspects on clinicopathological concepts and therapeutic challenges in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), arising from publications of the last 1.5 years. Recent findings The clinical criteria for diagnosis of PSP have been revised. Clinical variability of pathologically defined PSP and MSA makes the development of mature biomarkers for early diagnosis and biomarker-based trial design indispensable. Novel molecular techniques for biomarker supported diagnosis of PSP and MSA and for monitoring disease progression are being studied. Research in the pathophysiology of both diseases generates gradual progress in the understanding of the underlying processes. Several promising disease-modifying therapeutic approaches for PSP and MSA are now moving into clinical trials. Summary Recent research generates insights in the pathophysiological relevant processes and raises hope for earlier clinical diagnosis and disease-modifying therapies of patients with PSP and MSA.

• Publication year

  2018

• Venue

  Current Opinion in Neurology

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/WCO.0000000000000581PMID 29746401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple system atrophy and apolipoprotein E

  2018cited by this paper
• Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies

  2018cited by this paper
• Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study

  2018cited by this paper
• The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases

  2018cited by this paper
• Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?

  2018cited by this paper
• Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers

  2018cited by this paper
• [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy

  2018cited by this paper
• Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain

  2017cited by this paper
• Brain structural profile of multiple system atrophy patients with cognitive impairment

  2017cited by this paper
• Blood-based NfL

  2017cited by this paper
• Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome

  2017cited by this paper
• Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy

  2017cited by this paper
• Tau aggregates: where, when, why and what consequences?

  2017cited by this paper
• Profile of cognitive impairment and underlying pathology in multiple system atrophy

  2017cited by this paper
• Pure autonomic failure

  2017cited by this paper
• Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials

  2017cited by this paper
• Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

  2017cited by this paper
• Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia

  2017cited by this paper
• CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

  2017cited by this paper
• Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies

  2017cited by this paper
• Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

  2017cited by this paper
• Which ante mortem clinical features predict progressive supranuclear palsy pathology?

  2017cited by this paper
• Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping

  2017cited by this paper
• Additional file 5: Figure S5. of The release and trans-synaptic transmission of Tau via exosomes

  2017cited by this paper
• What is the evidence that tau pathology spreads through prion-like propagation?

  2017cited by this paper
• PERK activation mitigates tau pathology in vitro and in vivo

  2017cited by this paper
• Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

  2017cited by this paper
• Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration

  2017cited by this paper
• Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism

  2017cited by this paper
• Usefulness of diffusion-tensor MRI in the diagnosis of Parkinson variant of multiple system atrophy and Parkinson's disease: a valuable tool to differentiate between them?

  2017cited by this paper
• Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial

  2017cited by this paper
• MSA prions exhibit remarkable stability and resistance to inactivation

  2017cited by this paper
• Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go

  2017cited by this paper
• Manual MRI morphometry in Parkinsonian syndromes

  2017cited by this paper
• Natural history of pure autonomic failure: A United States prospective cohort

  2017cited by this paper
• Mesenchymal stem cells enhance α-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder

  2016cited by this paper
• Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies

  2016cited by this paper
• Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification

  2016cited by this paper
• Loss of Bin1 Promotes the Propagation of Tau Pathology.

  2016cited by this paper
• Volume of Interest Analysis of Spatially Normalized PRESTO Imaging to Differentiate between Parkinson Disease and Atypical Parkinsonian Syndrome

  2016cited by this paper
• The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach

  2016cited by this paper
• A genome-wide association study in multiple system atrophy

  2016cited by this paper
• Increased CSF neurogranin concentration is specific to Alzheimer disease

  2016cited by this paper
• Progression of brain atrophy in PSP and CBS over 6 months and 1 year

  2016cited by this paper
• Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature.

  2016cited by this paper
• How strong is the evidence that Parkinson's disease is a prion disorder?

  2016cited by this paper
• MAPT haplotype diversity in multiple system atrophy.

  2016cited by this paper
• Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy

  2015cited by this paper
• Variants associated with Gaucher disease in multiple system atrophy

  2015cited by this paper
• PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia

  2015cited by this paper
• Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation.

  2015cited by this paper
• The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases

  2014cited by this paper
• The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease

  2013cited by this paper
• A randomized trial of mesenchymal stem cells in multiple system atrophy

  2012cited by this paper
• Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy

  2011cited by this paper
• Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy.

  2011cited by this paper
• Second consensus statement on the diagnosis of multiple system atrophy

  2008cited by this paper
• Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms.

  2007cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper

• PET Imaging to Measure Neuroinflammation In Vivo.

  2024cites this paper
• microRNA and circRNA in Parkinson's Disease and atypical parkinsonian syndromes.

  2023cites this paper
• Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy: A Systemized Review of the Literature

  2023cites this paper
• Lewy body disease or diseases with Lewy bodies?

  2022cites this paper
• MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review

  2022cites this paper
• Retina thickness in atypical parkinsonism: a systematic review and meta-analysis

  2021cites this paper
• A case report of Multi System Atrophy (MSA) with cross over features of Progressive Supranuclear Palsy (PSP)

  2021cites this paper
• Cutaneous sensory and autonomic denervation in progressive supranuclear palsy

  2021cites this paper
• Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017

  2020cites this paper
• Neuroradiological and clinical features in ophthalmoplegia

  2019cites this paper
• PET markers of tau and neuroinflammation are co-localized in progressive supranuclear palsy

  2019cites this paper
• Clinical Updates and Recent Developments in Neuro-Ophthalmology

  2019cites this paper
• The Progressive Supranuclear Palsy: Past and Present Aspects

  2019cites this paper
• A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control

  2019cites this paper
• Dyskinesia in multiple system atrophy and progressive supranuclear palsy

  2019cites this paper
• Multiple system atrophy.

  2019cites this paper
• ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans

  2018cites this paper